奧米加干擾素

用途

• Treatment of FeLV and/or FIV (non-terminal clinical stages)
• FHV-1 facial dermatitis
• Treatment of parvovirus (enteric form)
• Treatment of atopic dermatitis
• Parvovirus

給藥方式

可能的副作用

• Hyperthermia (typically 3-6 hours post-dose)
• Vomiting
• Soft feces or mild diarrhea (cats)
• Transient fatigue or lethargy (cats)
• Slight decreases in RBCs, WBCs, and platelets (usually resolves within a week)
• Increased ALT (usually resolves within a week)
• Antibody formation in dogs (with prolonged or repeated treatment)
• Transient fatigue
• Hyperthermia
• Mild diarrhoea
• Decreased WBCs (leukopenia)
• Decreased platelets (thrombocytopenia)
• Decreased RBCs (anaemia)

注意事項與禁忌

• Concurrent vaccination in dogs (wait until fully recovered)
• Vaccination in cats during and after treatment (due to the immunosuppressive nature of FeLV/FIV)
• Substitution with human interferons (alpha, beta, or gamma)
• No specific contraindications available in the monograph
• Do not vaccinate dogs currently being treated until they have fully recovered. Cat vaccinations are contraindicated during and after treatment due to the underlying immunosuppressive retroviral infections. Intravenous administration in cats may cause an increased incidence and severity of adverse effects, though adverse effects in cats are generally uncommon. Dogs may develop neutralizing antibodies if treatment is prolonged beyond the labeled dosage period.

藥物相互作用

• Hepatotoxic drugs: May increase the risk of liver toxicity; use with caution.
• Myelosuppressive drugs: May increase the risk of bone marrow suppression; use with caution.
• Vaccines: Should not be administered concurrently until the animal has clinically recovered.
• Antibiotics: Improves prognosis; no negative interactions observed.
• NSAIDs: Improves prognosis; no negative interactions observed.

常見問題